U.S. Markets closed

Brandes Investments' Top 5 Buys in the 3rd Quarter

Brandes Investment Partners, the firm founded by Charles Brandes (Trades, Portfolio), disclosed in a quarterly filing that its top five buys for the third quarter were Cemex SAB de CV (NYSE:CX), Halliburton Co. (NYSE:HAL), Takeda Pharmaceutical Co. Ltd. (NYSE:TAK), Netgear Inc. (NASDAQ:NTGR) and United Therapeutics Corp. (NASDAQ:UTHR). Additionally, the firm disclosed this week it trimmed its holding of Avadel Pharmaceuticals PLC (NASDAQ:AVDL) according to GuruFocus Real-Time Picks, a Premium feature.


The firm follows investment teachings from Benjamin Graham: Brandes Investment Partners seeks out-of-favor companies that are trading at discounts to intrinsic value and holds them until the market recognizes the companies' true worth.

b3ba698d31601abe10e1954b8b9ca504.png

As of quarter-end, the firm's $3.87 billion equity portfolio contains 138 stocks, of which 11 are new positions. The top three sectors in terms of portfolio weight are financial services, health care and industrials.

5ebd1dc6ca796a030d1b41c2334b51f7.png

Real-time Sell: Avadel

Brandes Investment Partners disclosed on Nov. 29 a stake of 4,440,050 shares in Avadel, down 1,742,786 shares or 28.19% from the third quarter-end holding of 6,182,836 shares. The shares traded around $6.35 that day.

ef99b7b6e9b2e841f31037b6e99c9fac.png

The Dublin, Ireland-based drug company develops and commercializes branded pharmaceutical products, including controlled-release therapeutic products based on its proprietary drug delivery technologies in the U.S. According to GuruFocus, Avadel's cash-to-debt ratio of 0.58 underperforms 60.85% of global competitors, suggesting low financial strength.

3afcca2a4836d493f1ccb310985e0562.png

Cemex

Brandes Investment Partners added 9,324,366 shares of Cemex, increasing the stake 14.6% and the equity portfolio 0.95%. Shares averaged $3.67 during the quarter.

2d58a141fe5966138a392f8549cb935b.png

GuruFocus ranks the Mexican cement company's profitability 6 out of 10: Even though net margins are underperforming 52.38% of global competitors, Cemex's operating margin has increased approximately 4.20% per year on average over the past five years and is outperforming 61.52% of global building materials companies.

dbfe1dc0c58c2bbb14666f65acf6e2ec.png

Halliburton

Brandes Investment Partners added 1,186,284 shares of Halliburton, increasing the stake 75.69% and the equity portfolio 0.58%. Shares averaged $20.70 during the quarter.

8256990df0a3c1849c6bc9c8416583c4.png

GuruFocus ranks the Houston-based energy company's profitability 6 out of 10 on the heels of operating margins outperforming 62.91% of global competitors despite contracting approximately 9.30% per year on average over the past five years.

c26b96ad4c12ef72ca4c155718168588.png

Other gurus with holdings in Halliburton include Sarah Ketterer (Trades, Portfolio) and Dodge & Cox.

64a2ff9a0820b8d3b7f6793dcc2d9f4b.png

Takeda

The firm added 499,819 shares of Takeda, increasing the holding 37.21% and the equity portfolio 0.22%. Shares averaged $17.29 during the quarter.

83a53b1fe42f6895a0fa0465784e02f1.png

GuruFocus ranks the Japanese drug manufacturer's profitability 5 out of 10: Although the company's return on equity underperforms just 58.51% of global competitors, Takeda's operating margin is underperforming 62.27% of global drug manufacturers. Despite this, it has a solid Piotroski F-score of 5 out of 9.

3f06558004d92c141dda918a68c73bac.png

Netgear

The firm added 185,356 shares of Netgear, increasing the position 26.92% and the equity portfolio 0.15%. Shares averaged $31.37 during the quarter.

43c82f895c2a3319daf40209636f0f37.png

The San Jose, California-based company provides networking solutions through three business segments: Arlo, connected home and SMB. GuruFocus ranks Netgear's financial strength 8 out of 10 on several positive investing signs, which include robust interest coverage and a debt-to-equity ratio that outperforms 80.94% of global competitors.

United Therapeutics

Brandes Investment Partners added 74,963 shares of United Therapeutics, increasing the holding 33.74% and the equity portfolio 0.15%. Shares averaged $80.58 during the quarter.

aa39f40740e9c122c97ff22e0a12fa9c.png

The Silver Spring, Maryland-based biotech company develops drugs for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries. According to GuruFocus, United Therapeutics' cash-to-debt and debt-to-equity ratios are underperforming over 73% of global competitors, suggesting low financial strength.

38227bf3d98d67f71427e02b69a393f9.png

Disclosure: No positions.

Read more here:

  • John Paulson's Top 5 Buys in the 3rd Quarter
  • Stanley Druckenmiller's Top 4 Buys in the 3rd Quarter
  • Wallace Weitz's Major Consumer Cyclical Holdings



Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.